Скачать или смотреть The selective targeting of T-cell malignancies using a TRBC1-directed CAR T-cell therapy

Anna De Lucia, PhD student, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy, provides insight into the selective targeting of T-cell malignancies using a TRBC1-directed CAR T-cell therapy (CAR-T-One), which exploits the clonality of T-cells to recognize and eliminate malignant cells while sparing healthy T-cells. She highlights the rationale for developing this therapeutic approach and outlines the preclinical testing conducted thus far, including in vitro and in vivo experiments. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.